IL 22-FC Uses, Dosage, Side Effects and more
IL 22-FC is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
| Attribute | Details |
|---|---|
| Trade Name | IL 22-FC |
| Generic | Efmarodocokin alfa |
| Efmarodocokin alfa Other Names | Efmarodocokin alfa, IL 22-FC, IL-22Fc |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How IL 22-FC works
IL 22-FC is a human IL-22Fc IgG4 fusion protein that activates the IL-22 pathway being investigated for inflammatory diseases. Studies show activation of STAT3 in primary human hepatocytes and human colon cell lines.
